Diabetes News and Research

Latest Diabetes News and Research

Importance of cell-cell communication in ischaemia

A team from the Bristol Heart Institute have investigated the importance of cell-cell communication in regulating the formation of new blood vessels following the restriction in blood supply to the heart or back leg in mice.

29 Jun 2010

Alimera submits Iluvien NDA for DME to FDA

Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Iluvien®, (flucocinolone acetonide intravitreal insert), its investigational, sustained drug delivery system releasing sub-microgram levels of fluocinolone acetonide for the treatment of diabetic macular edema (DME).

29 Jun 2010

BBD reports analyze effectiveness and safety of statin use

A series of new reports from Consumer Reports Best Buy Drugs (BBD) caution that the benefits of statin use by children and some women may not outweigh the risks. Drugs to lower cholesterol - including statins - are the most commonly prescribed drugs in the U.S. and garnered more than $14 billion in sales last year.

29 Jun 2010

Individual cells react differently to complex signals: Study

Using new technology that allows scientists to monitor how individual cells react in the complex system of cell signaling, Stanford University researchers have uncovered a much larger spectrum of differences between each cell than ever seen before.

29 Jun 2010

Vitae earns $14M milestone payment from Boehringer Ingelheim

Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned a $14 million clinical milestone payment from Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies. Vitae's 11beta-hydroxysteroid dehydrogenase (HSD)-1 is targeted for the treatment of diabetes and metabolic syndrome-related diseases in a strategic alliance with Boehringer Ingelheim. The payment recognizes Boehringer Ingelheim's recent advancement of a small molecule inhibitor of 11beta-HSD-1 into Phase I clinical trials.

29 Jun 2010

First Edition: June 29, 2010

In this Kaiser Health News consumer column, Michelle Andrews writes: "Sarah Rose Nordgren works 25 to 30 hours a week as a waitress at an upscale restaurant in Chapel Hill, N.C. She also tutors high- schoolers on their college entrance essays and has an editorial internship at a book publisher. But if something were to go seriously wrong with her health, she'd be in trouble because none of her three jobs offers health insurance" (Kaiser Health News).

29 Jun 2010

Rosiglitazone therapy associated with increased risk for heart attack: Study

Eleven years after the introduction of the diabetes drug rosiglitazone, data from available clinical trials demonstrate an increased risk for heart attack associated with its use and suggest an unfavorable benefit-to-risk ratio, according to a report posted online today that will appear in the July 26 print issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

29 Jun 2010

Lantus and Apidra improve outcomes, decrease glycemic variability: Study

Sanofi-aventis announced today results of a study which demonstrated that patients using Lantus® (insulin glargine [rDNA origin] injection) once-daily and Apidra® (insulin glulisine [rDNA origin] injection) before meals reported improved patient reported outcomes and decreased glycemic variability versus premix analog insulin. Two abstracts from this study were highlighted at the American Diabetes Association's 70th Annual Scientific Sessions (ADA).

29 Jun 2010

Phytonutrient-based medical food and heart-healthy diet reduce CVD risk factors: Study

New research presented at the American Diabetes Association's 70th Scientific Sessions in Orlando, Florida on June 27, 2010 suggests that a medical food developed by Metagenics, Inc. called UltraMeal® PLUS 360° enhances the cardiovascular disease (CVD) risk-lowering benefits of a Mediterranean-style low-glycemic-load diet.

29 Jun 2010

Serotonin promotes beta cell expansion during pregnancy, offers possible cure for type 1 diabetes

Researchers funded by JDRF have discovered that the hormone, serotonin, may be involved in the increase of insulin-producing beta cells during pregnancy.

29 Jun 2010

Tranzyme reports positive results from TZP-102 Phase 2 study in diabetic patients with gastroparesis

Tranzyme Pharma announced positive top-line results today from a Phase 2, double-blind, placebo-controlled study evaluating TZP-102 capsules in diabetic patients with gastroparesis, a serious disorder characterized by the inability of the stomach to empty food efficiently. The study achieved a clinically meaningful and statistically significant improvement in critical gastroparesis-related symptoms. All three TZP-102 doses tested were effective, safe and well tolerated.

29 Jun 2010

Dapagliflozin in addition to insulin improves glycemic control in type 2 diabetics

Results from a 24-week Phase 3 clinical study demonstrated that the addition of the investigational drug dapagliflozin achieved reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c), in inadequately controlled type 2 diabetes patients who were treated with insulin (with or without oral anti-diabetes medications (OADs)), compared to placebo plus insulin (with or without OADs).

29 Jun 2010

Nearly 7% of sixth-graders in U.S. are severely obese

Nearly 7 percent of sixth-graders across the U.S. are severely obese, reveals a new study appearing online in the Journal of Adolescent Health.

29 Jun 2010

Daiichi Sankyo, Eli Lilly respond to ACCF/AHA clinical alert on FDA's clopidogrel boxed warning

Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).

29 Jun 2010

Aggressive pursuit of low blood pressure, cholesterol levels may not benefit patients with diabetes

A mathematical model suggests that aggressively pursuing low blood pressure and cholesterol levels may not benefit, and could even harm, some patients with diabetes, according to a report in the June 28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

29 Jun 2010

Family members who undergo gastric bypass surgery together experience better clinical outcomes

If you and a family member have gastric bypass together, chances are you'll both do much better than if you have surgery alone, according to a new study presented today at the 27th Annual Meeting of the American Society for Metabolic & Bariatric Surgery.

29 Jun 2010

School-based program lowers obesity and risk factors for type 2 diabetes in high risk youth

An intervention in middle schools lowered the obesity rate in students at highest risk for type 2 diabetes, those who started out overweight or obese in sixth grade, an NIH-funded study has found. However, schools that implemented the program did not differ from comparison schools in the study's primary outcome-the prevalence of overweight and obesity combined-which had declined 4 percent in both groups of schools by the end of the three-year study.

29 Jun 2010

Artificial pancreas holds promise for treating Type 1 diabetes

Shawna Wood would like nothing better than to go back to bed for another 24 hours of perfect blood sugar control. The 50-year old Wilsonville, Ore. woman has Type 1 diabetes, and she recently took part in a clinical trial of an automated replacement for her pancreas, which stopped producing insulin 9 years ago.

29 Jun 2010

Welchol plus metformin combination therapy reduces A1C, LDL-C levels in type 2 diabetes patients

Results of a new study demonstrated that initial combination therapy with Welchol® (colesevelam HCl) 3.75 g/d and metformin (initiated at 850 mg/d; uptitrated to 1700 mg/d thereafter) significantly improved glycemic and lipid control in drug-naive adult type 2 diabetes patients with high LDL cholesterol (LDL-C).

29 Jun 2010

Astellas presents ASP1941 selective SGLT2 inhibitor Phase 2 study results at 70th ADA

Astellas Pharma Inc. announced that the company presented results from a Japanese Phase 2 study conducted with ASP1941, a selective SGLT2 inhibitor, at the 70th Scientific Sessions of the American Diabetes Association (ADA) on June 26, 2010 (EST). ASP1941 is designed to block the re-absorption of glucose in the kidney and excrete glucose in the urine.

29 Jun 2010

Diabetes News and Research

Latest Diabetes News and Research

Importance of cell-cell communication in ischaemia

Alimera submits Iluvien NDA for DME to FDA

BBD reports analyze effectiveness and safety of statin use

Individual cells react differently to complex signals: Study

Vitae earns $14M milestone payment from Boehringer Ingelheim

First Edition: June 29, 2010

Rosiglitazone therapy associated with increased risk for heart attack: Study

Lantus and Apidra improve outcomes, decrease glycemic variability: Study

Phytonutrient-based medical food and heart-healthy diet reduce CVD risk factors: Study

Serotonin promotes beta cell expansion during pregnancy, offers possible cure for type 1 diabetes

Tranzyme reports positive results from TZP-102 Phase 2 study in diabetic patients with gastroparesis

Dapagliflozin in addition to insulin improves glycemic control in type 2 diabetics

Nearly 7% of sixth-graders in U.S. are severely obese

Daiichi Sankyo, Eli Lilly respond to ACCF/AHA clinical alert on FDA's clopidogrel boxed warning

Aggressive pursuit of low blood pressure, cholesterol levels may not benefit patients with diabetes

Family members who undergo gastric bypass surgery together experience better clinical outcomes

School-based program lowers obesity and risk factors for type 2 diabetes in high risk youth

Artificial pancreas holds promise for treating Type 1 diabetes

Welchol plus metformin combination therapy reduces A1C, LDL-C levels in type 2 diabetes patients

Astellas presents ASP1941 selective SGLT2 inhibitor Phase 2 study results at 70th ADA

Pharmaceutical Manufacturing - Industry Focus eBook eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Diabetes News and Research

Latest Diabetes News and Research

Pharmaceutical Manufacturing - Industry Focus eBook eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in